PaxMedica Inc (PXMD)

[Monksdream]

PXMD new 52 week low

[Monksdream]

PXMD new 52 week low

[Monksdream]

PXMD new 52 week low

[Monksdream]

PXMD new 52 week low

[Monksdream]

PXMD new 52 week low

[McMagyar]

Are they using aura I’m in IV for autism clinical?

[airman1]

Shorts all over it!!

[HJ72]

They always do .

[McMagyar]

They got stock from somewhere

[McMagyar]

Do they not think voucher possible?
Is IV solution used for Autism?

[airman1]

Shorts in full control; tanking the pps:
Continues to pull back!

[KOmani]

I lost a few hundred here as the shorts were brutal on it.

Good luck to anyone still trying to beat shorts.

I was thinking they got cleared on the second pop over $1, but that was not the case.

Now watch and see that they cover and let it fly now ....

[KOmani]

Looks good after the shorts stuffed it down to cover.

LMAO, they came back to stuff it below $1 again.

[Triple nickle]

Round two

[AJ Freely]

$PXMD - Up 28% Pre-Market/ Current Price $1.03
Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

[HJ72]

Waking up

[HJ72]

Buying low 76.8% insider ownership on a 2.85 million float…shorts are brave .

[Cadams05]

We need volume

[81vette]

357,000 shares short,could squeeze big

[81vette]

Insiders buying up 500%,buy vol up huge,almost no selling ,#1 on my scanner so I have to buy ,short is 40% of float

[da_stock_analyst]

#PXMD ?? NEXT SQUEEZE stock with 60%+ short interest and 493% CTB! Bullish chart! $PXMD

[Triple nickle]

Doing good now

[alchemytrader]

2.63. tiny 700k float. 70% institutional owned. coulda squeeze. lets see.

[Triple nickle]

Dip and rip

[masterofdisaster]

Don't miss out here!

[masterofdisaster]

Could go parabolic soon. Been adding every day

[masterofdisaster]

We could see a huge move here soon!!!

[TheFinalCD]

PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
https://finviz.com/quote.ashx?t=PXMD&ty=c&ta=1&p=d

[heyitsmeagain]

Great play hopefully Tirx follows

[Awl416]

Nice ah movement

[dinogreeves]

Bad trade, figured they had a agreement with Lincoln Park for funding, this stock is not a good bet for traders. Lincoln Park shorting it, even though on the contract stipulation that no shorting or lending their stock for shorting purposes. Overall a bad trade.

[dinogreeves]

PXMD short squeeze play for tomorrow if news hits premarket it will squeeze real hard.

[csud1]

Any volume at all and this is going to fly

[TheFinalCD]

thx,I missed this today

[csud1]

Looks like I will be around a bit with my 2.50 entry.

[crudeoil24]

BOOM > $$$$$

[INFINITI]

PaxMedica Soars on Equity Deal with Lincoln Park Capital

Source: TipRanks
Shares of clinical-stage biopharmaceutical company PaxMedica (NASDAQ:PXMD) are soaring higher in the pre-market session today after PXMD entered into an equity investment agreement with Lincoln Park Capital. Under the agreement, PXMD has the right without being obligated to sell its shares worth up to $20 million to Lincoln over a time span of 30 months. Further, PXMD plans to use the proceeds from this sale for working capital needs and to support its growth. Importantly, the move provides PXMD maneuvrability as it advances towards the manufacturing validation of intravenous suramin. Now, the company is preparing to submit the NDA for the human African trypanosomiasis late next year.
https://www.tipranks.com/news/paxmedica-soars-on-equity-deal-with-lincoln-park-capital?utm_source=advfn.com&utm_medium=referral

[INFINITI]

Nice News!!!!

[rockfysh]

Nice!

[subslover]

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
November 17 2022 - 08:29PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").
Under the terms and conditions of the Agreement, including effectiveness of a related registration statement, the Company has the right, but not the obligation, to sell up to $20 million of its shares of common stock to Lincoln Park over a 30-month period, subject to certain limitations. Any common stock that is sold to Lincoln Park will occur at a purchase price that is determined by prevailing market prices at the time of each sale with no upper limits to the price Lincoln Park may pay to purchase the common stock. The Agreement does not contain any restrictions on the use of any of the proceeds and there are no financial covenants, participation rights, rights of first refusal, or penalties. There are no warrants, derivatives, financial or business covenants associated with the Agreement and Lincoln Park has agreed not to cause or engage in any direct or indirect short selling or hedging of the Company’s common stock. The Company issued common shares to Lincoln Park as consideration for Lincoln Park’s commitment to purchase the Company’s common stock under the Agreement. The Company intends to use the net proceeds from the sale of its common stock under the Agreement for working capital and general corporate purposes to support its growth.

Howard Weisman, Chief Executive Officer of PaxMedica, commented, “This financing affords us additional flexibility as we move toward completing manufacturing validation of intravenous suramin in preparation for NDA submission in late 2023 for the Human African Trypanosomiasis (brucei rhodesiense). The NDA, when submitted, is also expected to trigger an application for a Priority Review Voucher “(PRV”) which the company plans to monetize upon receipt.”

Further details relating to the Agreement and this transaction will be contained in the Current Report on Form 8-K the Company intends to file with the Securities and Exchange Commission (the “SEC”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock, nor shall there be any sale of shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About PaxMedica
PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future even

[subslover]

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
November 17 2022 - 08:29PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").
Under the terms and conditions of the Agreement, including effectiveness of a related registration statement, the Company has the right, but not the obligation, to sell up to $20 million of its shares of common stock to Lincoln Park over a 30-month period, subject to certain limitations. Any common stock that is sold to Lincoln Park will occur at a purchase price that is determined by prevailing market prices at the time of each sale with no upper limits to the price Lincoln Park may pay to purchase the common stock. The Agreement does not contain any restrictions on the use of any of the proceeds and there are no financial covenants, participation rights, rights of first refusal, or penalties. There are no warrants, derivatives, financial or business covenants associated with the Agreement and Lincoln Park has agreed not to cause or engage in any direct or indirect short selling or hedging of the Company’s common stock. The Company issued common shares to Lincoln Park as consideration for Lincoln Park’s commitment to purchase the Company’s common stock under the Agreement. The Company intends to use the net proceeds from the sale of its common stock under the Agreement for working capital and general corporate purposes to support its growth.

Howard Weisman, Chief Executive Officer of PaxMedica, commented, “This financing affords us additional flexibility as we move toward completing manufacturing validation of intravenous suramin in preparation for NDA submission in late 2023 for the Human African Trypanosomiasis (brucei rhodesiense). The NDA, when submitted, is also expected to trigger an application for a Priority Review Voucher “(PRV”) which the company plans to monetize upon receipt.”

Further details relating to the Agreement and this transaction will be contained in the Current Report on Form 8-K the Company intends to file with the Securities and Exchange Commission (the “SEC”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock, nor shall there be any sale of shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About PaxMedica
PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future even

[Soulman856]

Making a move here this week?looks like it might squeeze

[subslover]

That's enough of my private life.lol

[TheFinalCD]

who's we


lol


weeeeeee

[subslover]

We are moving back up! :)

[Invest-in-America]

Don't call him that --- he takes OFFENSE!! (Which begs the question: Does GOD take offense at being called "GOD"???)

[subslover]

Holy stock God's man! WOW

[TheFinalCD]

whatta dip&rip

3.67-5.43

[subslover]

Really very sweet! CONGRATS to you and longs here

[Invest-in-America]

Sure looks that way!!